Pfizer to present neuroscience pipeline at AD meeting

Global pharmaceutical leviathan Pfizer will present nine abstracts from its Alzheimer's disease R&D program, including three on two promising investigational therapies in the early stages of development, at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease in Chicago, July 26-31.

The company will also host an analyst briefing at the ICAD to review its neuroscience pipeline and platform on July 28. In addition, Pfizer will sponsor a satellite symposium, titled Innovative Approaches to Alzheimer's Disease: Developing the Next Generation of Treatment, on July 29.

"With the expected huge increase in the incidence of Alzheimer's disease worldwide in the next 25 years, Pfizer's neuroscience team has made this devastating illness our highest priority," said Liam Ratcliffe, senior vice president and development head for Pfizer Neuroscience. "With new insights into the underlying causes of Alzheimer's discovered in only the past few years, our scientists are working to develop new medicines that improve memory and other cognitive function, and importantly halt or significantly slow the progression of the disease. We are also working on approaches that could lead to earlier and better diagnosis," he added.